APA (7th ed.) Citation

Kremer, J. M., Cohen, S., Wilkinson, B. E., Connell, C. A., French, J. L., Gomez-Reino, J., . . . Zwillich, S. H. (2012). A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis & rheumatology (Hoboken, N.J.), 64(4), 970-981. https://doi.org/10.1002/art.33419

Chicago Style (17th ed.) Citation

Kremer, Joel M., et al. "A Phase IIb Dose-ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination with Background Methotrexate in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone." Arthritis & Rheumatology (Hoboken, N.J.) 64, no. 4 (2012): 970-981. https://doi.org/10.1002/art.33419.

MLA (9th ed.) Citation

Kremer, Joel M., et al. "A Phase IIb Dose-ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination with Background Methotrexate in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone." Arthritis & Rheumatology (Hoboken, N.J.), vol. 64, no. 4, 2012, pp. 970-981, https://doi.org/10.1002/art.33419.